Lisata Therapeutics, Inc. (LSTA) Stock

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing cellular therapies aimed at reversing disease and promoting tissue regeneration. One of its prominent product candidates is HONEDRA, which has received SAKIGAKE designation and is currently undergoing Phase II clinical trials for treating critical limb ischemia. Additionally, the company is progressing XOWNA through Phase IIb clinical trials for the treatment of coronary microvascular dysfunction, highlighting its commitment to addressing diverse medical challenges. Lisata Therapeutics is also advancing CLBS201, a CD34+ cell therapy designed to benefit pre-dialysis patients suffering from chronic kidney disease.

Formerly known as NeoStem, Inc., and subsequently as Caladrius Biosciences, Inc. until September 2022, Lisata Therapeutics has a rich history in biopharmaceutical innovation since its incorporation in 1980. Headquartered in Basking Ridge, New Jersey, the company continues to expand its therapeutic portfolio and explore new avenues in cellular medicine to enhance patient outcomes globally. Its strategic focus on cutting-edge research and development underscores its mission to transform healthcare through pioneering cellular therapies.

Lisata Therapeutics, Inc. stands at the forefront of advancing novel treatment modalities that harness the potential of cellular therapies. With a legacy of innovation spanning several decades, the company remains committed to pushing the boundaries of biopharmaceutical science to address unmet medical needs and improve the lives of patients worldwide.